𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

✍ Scribed by Afshar Amiri; Ahmad-Ali Noorbala; Ali-Akbar Nejatisafa; Abolfazl Ghoreishi; Mohammad-Kamran Derakhshan; Mohammad-Reza Khodaie-Ardakani; Mohammad Hajiazim; Maedeh Raznahan; Shahin Akhondzadeh

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
100 KB
Volume
23
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI‐B), at low doses would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far. This study was designed to investigate the effect of selegiline added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in an 8 week, double blind and randomized clinical trial.

Methods

Eligible participants in this study were 40 patients with chronic schizophrenia. All patients were inpatients and were in the active phase of the illness, and met DSM‐IV‐TR criteria for schizophrenia. Patients were allocated in a random fashion, 20 to risperidone 6 mg/day plus selegiline 10 mg/day (5 mg bid) and 20 to risperidone 6 mg/day plus placebo. The principal measure of the outcome was Positive and Negative Syndrome Scale (PANSS).

Results

Although both protocols significantly decreased the score of the positive, negative, and general psychopathological symptoms over the trial period, the combination of risperidone and selegiline showed a significant superiority over risperidone alone in decreasing negative symptoms and PANSS total scores.

Conclusion

The present study indicates selegiline as a potential adjunctive treatment strategy for the negative symptoms of schizophrenia. Nevertheless, results of larger controlled trials are needed before recommendation for a broad clinical application can be made. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Mirtazapine add-on therapy in the treatm
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial
✍ Michael Berk; Clarissa S. Gama; Suresh Sundram; Harry Hustig; Les Koopowitz; Rus 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract ## Objective Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, parti

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Glucosamine sulfate in the treatment of
Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator
✍ Gabriel Herrero-Beaumont; José Andrés Román Ivorra; María del Carmen Trabado; Fr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 3 views

## Abstract ## Objective To assess the effects of the prescription formulation of glucosamine sulfate (1,500 mg administered once daily) on the symptoms of knee osteoarthritis (OA) during a 6‐month treatment course. ## Methods Three hundred eighteen patients were enrolled in this randomized, pla

Double-blind, placebo-controlled study t
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism
✍ Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## Abstract Drooling is a frequent symptom in Parkinson's disease (PD), occurring in almost 75% of all patients. Although it is now well known that drooling in PD is the result of swallowing difficulties rather than excessive saliva production, few treatments have been developed to reduce it. Clini

A randomized, double-blind, placebo cont
A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome
✍ Ludger Grote; Lena Leissner; Jan Hedner; Jan Ulfberg 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 1 views

## Abstract Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤

Alefacept in combination with methotrexa
Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study
✍ Philip J. Mease; Dafna D. Gladman; Edward C. Keystone 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA). ## Methods Patients were eligible for this randomized, double‐blind, placebo‐controlled trial if they were ages 18–70 years and had act